BAJAJ BROKING

Notification close image
No new Notification messages
card image
Travel Food Services IPO is Open!
Apply for the Travel Food Services IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

19941

524500

KILITCH

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

KILITCH DRUGS INDIA LTD performance

Today’s low

Today’s high

₹ 426.60 ₹ 452.00
₹ 430.45

52 week low

52 week high

₹ 299.95 ₹ 499.00
₹ 430.45

Open Price

₹ 449.90

Prev. Close

₹ 443.80

Volume (Shares)

50052.00

Total traded value

₹ 215.44

Upper Circuit

₹ 465.95

Lower Circuit

₹ 421.65

info

KILITCH DRUGS INDIA LTD Share Price Update

As of the latest trading session, KILITCH DRUGS INDIA LTD share price is currently at ₹ 430.45, which is down by ₹ -13.34 from its previous closing. Today, the stock has fluctuated between ₹ 426.60 and ₹ 452.00. Over the past year, KILITCH DRUGS INDIA LTD has achieved a return of 22.02 %. In the last month alone, the return has been 2.00 %. Read More...

Investment Returns

Over 1 Month 2.00% Over 3 Months 27.80% Over 6 Months 24.33% Over 1 Year 22.02%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

KILITCH DRUGS INDIA LTD fundamentals


  • Market cap (Cr)

    692.30

  • P/E Ratio (TTM)

    22.39

  • Beta

    0.72

  • Book Value / share

    157.27

  • Return on equity

    8.39%

  • EPS (TTM)

    19.37

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    11.37

info icon alternate text
  • Market cap (Cr)

    697.30

  • P/E Ratio (TTM)

    22.39

  • Beta

    0.47

  • Book Value / share

    157.27

  • Return on equity

    8.39%

  • EPS (TTM)

    19.37

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    11.37

info icon alternate text

KILITCH DRUGS INDIA LTD Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars MAR 2025 (Values in Cr)
Revenue 56.30
Operating Expense 43.62
Net Profit 11.37
Net Profit Margin (%) 20.19
Earnings Per Share (EPS) 7.07
EBITDA 16.23
Effective Tax Rate (%) 24.13
Particulars DEC 2024 (Values in Cr)
Revenue 46.51
Operating Expense 39.36
Net Profit 6.88
Net Profit Margin (%) 14.79
Earnings Per Share (EPS) 4.28
EBITDA 10.48
Effective Tax Rate (%) 27.73
Particulars SEP 2024 (Values in Cr)
Revenue 45.35
Operating Expense 40.58
Net Profit 8.85
Net Profit Margin (%) 19.51
Earnings Per Share (EPS) 5.50
EBITDA 11.40
Effective Tax Rate (%) 16.35
Particulars JUN 2024 (Values in Cr)
Revenue 33.42
Operating Expense 31.04
Net Profit 4.05
Net Profit Margin (%) 12.11
Earnings Per Share (EPS) 2.52
EBITDA 6.43
Effective Tax Rate (%) 27.54
Particulars MAR 2024 (Values in Cr)
Revenue 39.14
Operating Expense 34.76
Net Profit 3.64
Net Profit Margin (%) 9.29
Earnings Per Share (EPS) 2.26
EBITDA 6.11
Effective Tax Rate (%) 30.79
Particulars MAR 2025 (Values in Cr)
Revenue 181.59
Operating Expense 154.62
Net Profit 31.16
Net Profit Margin (%) 17.15
Earnings Per Share (EPS) 19.37
EBITDA 44.56
Effective Tax Rate (%) 23.42
Particulars MAR 2024 (Values in Cr)
Revenue 131.60
Operating Expense 114.44
Net Profit 17.57
Net Profit Margin (%) 13.35
Earnings Per Share (EPS) 11.03
EBITDA 26.50
Effective Tax Rate (%) 24.75
Particulars MAR 2023 (Values in Cr)
Revenue 117.78
Operating Expense 102.94
Net Profit 15.72
Net Profit Margin (%) 13.34
Earnings Per Share (EPS) 10.09
EBITDA 21.77
Effective Tax Rate (%) 19.17
Particulars MAR 2022 (Values in Cr)
Revenue 105.16
Operating Expense 95.78
Net Profit 10.53
Net Profit Margin (%) 10.01
Earnings Per Share (EPS) 6.76
EBITDA 15.55
Effective Tax Rate (%) 24.40
Particulars MAR 2021 (Values in Cr)
Revenue 70.02
Operating Expense 66.70
Net Profit 6.16
Net Profit Margin (%) 8.79
Earnings Per Share (EPS) 3.98
EBITDA 9.40
Effective Tax Rate (%) 17.97
Particulars MAR 2024 (Values in Cr)
Book Value / Share 109.62
ROE % 8.28
ROCE % 13.30
Total Debt to Total Equity 0.16
EBITDA Margin 18.62
Particulars MAR 2023 (Values in Cr)
Book Value / Share 94.08
ROE % 5.70
ROCE % 10.24
Total Debt to Total Equity 0.15
EBITDA Margin 14.79
Particulars MAR 2022 (Values in Cr)
Book Value / Share 89.26
ROE % 4.03
ROCE % 6.34
Total Debt to Total Equity 0.13
EBITDA Margin 10.55
Particulars MAR 2021 (Values in Cr)
Book Value / Share 82.05
ROE % 2.41
ROCE % 3.51
Total Debt to Total Equity 0.11
EBITDA Margin 9.90
Particulars MAR 2020 (Values in Cr)
Book Value / Share 76.62
ROE % -0.18
ROCE % 0.56
Total Debt to Total Equity 0.09
EBITDA Margin 5.12
Particulars MAR 2024 (Values in Cr)
Book Value / Share 138.61
ROE % 8.39
ROCE % 10.74
Total Debt to Total Equity 0.13
EBITDA Margin 20.23
Particulars MAR 2023 (Values in Cr)
Book Value / Share 122.53
ROE % 8.41
ROCE % 9.89
Total Debt to Total Equity 0.11
EBITDA Margin 18.63
Particulars MAR 2022 (Values in Cr)
Book Value / Share 112.65
ROE % 6.18
ROCE % 7.82
Total Debt to Total Equity 0.10
EBITDA Margin 14.92
Particulars MAR 2021 (Values in Cr)
Book Value / Share 105.16
ROE % 3.32
ROCE % 4.20
Total Debt to Total Equity 0.09
EBITDA Margin 11.90
Particulars MAR 2020 (Values in Cr)
Book Value / Share 98.25
ROE % 1.92
ROCE % 2.67
Total Debt to Total Equity 0.07
EBITDA Margin 9.03
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 19.64
Total Assets 240.06
Total Liabilities 240.06
Total Equity 175.67
Share Outstanding 16082319
Price to Book Ratio 2.81
Return on Assets (%) 6.08
Return on Capital (%) 7.04
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 19.97
Total Assets 219.52
Total Liabilities 219.52
Total Equity 150.57
Share Outstanding 15582319
Price to Book Ratio 1.14
Return on Assets (%) 4.75
Return on Capital (%) 6.05
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 10.06
Total Assets 209.84
Total Liabilities 209.84
Total Equity 140.29
Share Outstanding 15582319
Price to Book Ratio 1.49
Return on Assets (%) 3.51
Return on Capital (%) 4.58
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 12.50
Total Assets 203.17
Total Liabilities 203.17
Total Equity 129.47
Share Outstanding 15494544
Price to Book Ratio 0.77
Return on Assets (%) 1.85
Return on Capital (%) 2.61
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 2.79
Total Assets 142.83
Total Liabilities 142.83
Total Equity 120.47
Share Outstanding 15434190
Price to Book Ratio 0.83
Return on Assets (%) 0.58
Return on Capital (%) 0.63
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 18.62
Total Assets 287.47
Total Liabilities 287.47
Total Equity 222.92
Share Outstanding 16082319
Price to Book Ratio 2.81
Return on Assets (%) 6.11
Return on Capital (%) 6.91
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 17.96
Total Assets 252.41
Total Liabilities 252.41
Total Equity 195.93
Share Outstanding 15582319
Price to Book Ratio 1.14
Return on Assets (%) 6.22
Return on Capital (%) 7.22
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2.44
Total Assets 232.29
Total Liabilities 232.29
Total Equity 178.03
Share Outstanding 15582129
Price to Book Ratio 1.49
Return on Assets (%) 4.53
Return on Capital (%) 5.31
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 5.77
Total Assets 195.84
Total Liabilities 195.84
Total Equity 162.93
Share Outstanding 15494544
Price to Book Ratio 0.77
Return on Assets (%) 3.14
Return on Capital (%) 3.47
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 2.72
Total Assets 174.11
Total Liabilities 174.11
Total Equity 151.64
Share Outstanding 15434190
Price to Book Ratio 0.83
Return on Assets (%) 2.55
Return on Capital (%) 2.72
Particulars MAR 2024 (Values in Cr)
Net Income 19.35
Cash from Operations 6.88
Cash from Investing -9.54
Cash from Financing 8.80
Net change in Cash -0.88
Free Cash Flow 13.33
Particulars MAR 2023 (Values in Cr)
Net Income 12.01
Cash from Operations 6.91
Cash from Investing 7.91
Cash from Financing -0.71
Net change in Cash 9.78
Free Cash Flow 10.72
Particulars MAR 2022 (Values in Cr)
Net Income 9.61
Cash from Operations 8.31
Cash from Investing -15.25
Cash from Financing 7.02
Net change in Cash -2.43
Free Cash Flow 16.52
Particulars MAR 2021 (Values in Cr)
Net Income 5.11
Cash from Operations 46.67
Cash from Investing -37.56
Cash from Financing 1.61
Net change in Cash 9.70
Free Cash Flow 82.96
Particulars MAR 2020 (Values in Cr)
Net Income 1.60
Cash from Operations 6.71
Cash from Investing -10.45
Cash from Financing 0.84
Net change in Cash -5.14
Free Cash Flow 17.21
Particulars MAR 2024 (Values in Cr)
Net Income 23.35
Cash from Operations -4.15
Cash from Investing -10.09
Cash from Financing 11.40
Net change in Cash -9.88
Free Cash Flow 2.36
Particulars MAR 2023 (Values in Cr)
Net Income 19.44
Cash from Operations 10.42
Cash from Investing 6.24
Cash from Financing 3.04
Net change in Cash 15.38
Free Cash Flow 13.97
Particulars MAR 2022 (Values in Cr)
Net Income 13.92
Cash from Operations 7.74
Cash from Investing -16.08
Cash from Financing 7.55
Net change in Cash -3.32
Free Cash Flow 15.94
Particulars MAR 2021 (Values in Cr)
Net Income 7.50
Cash from Operations 7.13
Cash from Investing -5.34
Cash from Financing 2.27
Net change in Cash 3.05
Free Cash Flow 7.55
Particulars MAR 2020 (Values in Cr)
Net Income 5.22
Cash from Operations 9.53
Cash from Investing -10.08
Cash from Financing 1.44
Net change in Cash -1.34
Free Cash Flow 10.54
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.45 27.82 1.99 279.33 34.11 / 77.70
BLISS GVS PHARMA LTD. 156.00 19.50 1.56 1643.78 103.10 / 184.95
CIPLA LTD. 1513.50 23.76 3.91 122246.58 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 328.70 12.58 2.66 967.40 170.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.45 36.45 5.76 279.33 34.11 / 77.70
AMRUTAJAN HEALTH LTD 712.85 40.55 6.30 2060.89 548.05 / 861.40
ASTRAZENECA PHARMA INDIA LTD. 9090.60 129.83 29.50 22726.50 6222.35 / 10653.05
BLISS GVS PHARMA LTD. 156.00 23.82 1.55 1643.78 103.10 / 184.95

KILITCH DRUGS INDIA LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
430.45 -3.00 redarrow
red-green-graph indicator
10 Bearish
6 Bullish
  • 5 Days 437.10
  • 26 Days 436.10
  • 10 Days 437.30
  • 50 Days 422.70
  • 12 Days 437.50
  • 100 Days 396.30
  • 20 Days 437.60
  • 200 Days 370.00
447.23 PIVOT

First Support

434.47

First Resistance

456.57

Second Support

425.13

Second Resistance

469.33

Third Support

412.37

Third Resistance

478.67

RSI

46.92

ADX

27.41

MACD

1.44

Williams % R

-64.58

Commodity Channel Index (CCI)

-44.35

Date

2025-05-29

Week

41415.00

Same Day

33581.00

Month

34706.00

1 Year

0.73

3 Year

0.61

Over 1 Month

2.00%

down

Over 1 Year

22.02%

down

Over 3 Months

27.80%

down

Over 3 Years

39.31%

down

Over 6 Months

24.33%

down

Over 5 Years

35.97%

down

KILITCH DRUGS INDIA LTD shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
30.76%
Promoter Holdings
69.23%
FII
0.0%
DII
0.0%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Kilitch Company (pharma) Limited 6629342.0 (41.22%) Shareholding of Promoter and Promoter Group
Bhavin Mukund Mehta 2523138.0 (15.69%) Shareholding of Promoter and Promoter Group
Mukund Mehta 1140647.0 (7.09%) Shareholding of Promoter and Promoter Group
Mira Bhavin Mehta 841046.0 (5.23%) Shareholding of Promoter and Promoter Group
Dipak Kanayalal Shah 500250.0 (3.11%) Public Shareholding
Shreni Shares Limited 164604.0 (1.02%) Public Shareholding

News

Left Arrow
Right Arrow

KILITCH DRUGS INDIA LTD corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
20 Sep 2019 0.5 Final 24 Sep 2019 Equity shares
18 Sep 2018 0.5 Final 20 Sep 2018 Equity shares
24 Sep 2012 30.0 Special 25 Sep 2012 Equity shares
18 Aug 2011 1.0 Final 23 Aug 2011 Equity shares
14 Oct 2010 1.0 Final 15 Oct 2010 Equity shares
10 Sep 2009 1.0 Final 12 Sep 2009 Equity shares
10 Sep 2008 1.0 Final 12 Sep 2008 Equity shares
15 Nov 2007 1.0 Interim 16 Nov 2007 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
20 Sep 2019 0.5 Final 24 Sep 2019 Equity shares
18 Sep 2018 0.5 Final 20 Sep 2018 Equity shares
24 Sep 2012 30.0 Special 25 Sep 2012 Equity shares
18 Aug 2011 1.0 Final 23 Aug 2011 Equity shares
14 Oct 2010 1.0 Final 15 Oct 2010 Equity shares
10 Sep 2009 1.0 Final 12 Sep 2009 Equity shares
10 Sep 2008 1.0 Final 12 Sep 2008 Equity shares
15 Nov 2007 1.0 Interim 16 Nov 2007 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

KILITCH DRUGS INDIA LTD Share Price

Kilitch Drugs (India) Limited (KDIL), incorporated in May, 1992 is the one of the leading and fastest growing pharmaceutical companies in the world, manufacturing, supplying and marketing broad range of pharmaceutical formulations in the various dosage forms like Solid, Liquid and Parental across the globe. Their extensive research efforts have led to development of comprehensive, diverse and highly complementary portfolio of medicines targeting a wide spectrum of chronic and acute treatments which includes Sterile dosages namely Injectables & Ophthalmic, Effervescent tablets & Granules, Tablets & Capsules, OTC range covering varied Nutraceuticals & Cosmetics and Medical devices.

The Company is engaged in development, manufacturing and marketing of quality finished dosages. The Company is one of the most reliable manufacturer of injectables in India and one of the largest manufacturer of cephalosporins in Africa having its manufacturing unit located in India and Ethiopia. Its services range from manufacturing to marketing a host of formulations in all dosage forms i.e. solid, liquid and parenteral forms of creating safe pharmaceutical solutions.

The Company went public in Feb.'94 to set up a pharmaceutical formulation plant at Thane to manufacture pharmaceutical products in the form of tablets, capsules,liquid orals, ointments, creams and injectables. Even before the plant was commissioned, the company came out with a rights issue in Oct.'95 to expand the injectible capacity. Commercial production at the plant at Thane commenced in 1996. The company has two divisions - O T C and ethical.

A Pharmaceutical formulation plant at Sana'a Republic of Yemen was set up at a cost of Rs 15 crore by entering into an agreement with Al-Fath Trading Corporation.It also entered into an agreement with a Miami company for the export of their medicine to West Indies, south and central America.

The company entered into a contract with one of the leading company in the Republic of Yemen which it had set up at a cost of Rs 2.5-cr tanning unit, which was implemented in the year 1995-96. The company had set up a bulk drug unit at Patalganga, Maharashtra for producing raw materials for formulations. The company exports to Sudan, Yemen, middle-east, Miami and certain south American companies.

KDIL started marketing a range of injectables from the factory on ethical basis. The company also introduced a new product clue-plus, Bon-Bon Gripe Water and Kilitch Balm.

The Company launched a new product 'BENIN' in the market in 2011. During the year 2011-12, the Company sold its business located at Paonta Sahib, Himachal Pradesh as a going concern on a slump sale basis along with transfer of services set forth in the Business Transfer Agreement (BTA). The undertaking was sold and transferred on 28th February 2012 after getting all the necessary clearances as indicated in the BTA. It retained its Name, Trademark (Kilitch) and all other properties and assets at Mumbai. It transferred certain products by entering into a Product Transfer Agreement (PTA) with Akorn India Pvt. Ltd. (AIPL) by which the right to manufacture certain products by the Company at Mumbai were sold to AIPL.

Parent organization Indian Private
NSE symbol KILITCH
Founded 1992
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Kilitch Drugs (India) Ltd?

Answer Field

Kilitch Drugs (India) Ltd share price is for NSE ₹ 430.45 & for BSE ₹ 430.00 as on Jul 04 2025 03:30 PM.

What is the Market Cap of Kilitch Drugs (India) Ltd Share?

Answer Field

The market cap of Kilitch Drugs (India) Ltd for NSE ₹ 692.26 & for BSE ₹ 691.53 as on Jul 04 2025 03:30 PM.

What is the 52 Week High and Low of Kilitch Drugs (India) Ltd?

Answer Field

The 52 Week High and Low of Kilitch Drugs (India) Ltd for NSE is ₹ 499.00 and ₹ 299.95 and for BSE is ₹ 500.05 and ₹ 271.30.

What is 1 year return for Kilitch Drugs (India) Ltd?

Answer Field

The 1 year returns on the stock has been 22.02%.

What is the P/E Ratio of Kilitch Drugs (India) Ltd Share?

Answer Field

As on Jul 04 2025 03:30 PM the price-to-earnings (PE) ratio for Kilitch Drugs (India) Ltd share is 22.39.

What is the PB ratio of Kilitch Drugs (India) Ltd Share?

Answer Field

As on Jul 04 2025 03:30 PM, the price-to-book (PB) ratio for Kilitch Drugs (India) Ltd share is 157.27.

How to Buy Kilitch Drugs (India) Ltd Share?

Answer Field

You can trade in Kilitch Drugs (India) Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Kilitch Drugs (India) Ltd Share on Bajaj Broking App?

Answer Field

To buy Kilitch Drugs (India) Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Kilitch Drugs (India) Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|